Iterum Therapeutics plc — Director's Dealing 2021

Dec 14, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Iterum Therapeutics plc (ITRM)
CIK: 0001659323
Period of Report: 2021-12-10

Reporting Person: Puttagunta Sailaja (Chief Medical Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-12-10	Share Option (Right to Buy)	$0.48	A	1800000	Acquired	2031-12-09	Ordinary Shares (1800000)	Direct
2021-12-10	Restricted Share Units	$	A	500000	Acquired		Ordinary Shares (500000)	Direct

Footnotes

F1: The shares underlying this option shall vest at a rate of twenty-five percent of the total number of shares on the one-year anniversary of December 1, 2021 and the remaining 75% will vest in equal monthly installments thereafter until December 1, 2025, subject to the Reporting Person providing continuous service to the Issuer on each relevant vesting date.

F2: Each restricted share unit ("RSU") represents the contingent right to receive one ordinary share upon vesting of the RSU.

F3: Subject to the Reporting Person providing continuous service to the Issuer on each relevant vesting date and the other terms and conditions of the Issuer's 2021 Inducement Equity Incentive Plan, the RSUs shall vest over four years with 25% of the RSUs vesting on each one-year anniversary of December 1, 2021, such that the total number of RSUs shall be fully vested by December 1, 2025.